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Objective:  Antimicrobial agents are commonly used in ambulatory care settings.  Our objective 23 
was to examine national-level patterns of contraindications between oral antibacterial or 24 
antifungal agents and patients’ other oral medications in the U.S ambulatory care setting. 25 
Methods: This cross-sectional study included multiple year pooled data (2003-2011) from the 26 
National Ambulatory Medical Care Survey (NAMCS) and the National Hospital Ambulatory 27 
Medical Care Survey (NHAMCS Outpatient Department). Visits by adults (age ≥ 18 years) in 28 
ambulatory settings in US who were prescribed oral antibacterial or antifungal agents were 29 
evaluated for potential drug-drug interaction contraindications. Findings with Relative Standard 30 
Error > 30% or unweighted sample size < 30 were not reported as these were deemed unreliable 31 
estimates. 32 
Results:  From 2003 to 2011, there were 1,235,000 outpatient visits (proportion = 0.52%, 95% 33 
CI 0.29 to 0.74%) in which a patient was prescribed an antimicrobial agent associated with a 34 
contraindicated drug-drug interaction. The most prevalent antimicrobials with contraindicated 35 
combination among outpatients were simultaneous use of macrolide-containing products 36 
(erythromycin or clarithromycin) with statin medication-containing products (simvastatin or 37 
lovastatin) (841,864 visits, proportion = 1.91%, 95% CI 0.96 to 2.86%). The next most common 38 
combination was use of fluoroquinolones with antiarrhythmic agents (amiodarone, sotalol, 39 
quinidine, or procainamide) (365,622 visits, proportion = 0.19%, 95% CI 0.06 to 0.32%). 40 
Conclusion:  Providers should be aware of potential contraindicated drug-drug interactions when 41 
prescribing antibiotics, especially macrolides and fluoroquinolones. 42 
 43 
 44 
 45 
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Introduction 46 
Antimicrobial agents are commonly used in patients in the ambulatory care setting.1 The most 47 
common diseases they used for are respiratory conditions, skin/mucosal conditions, and urinary 48 
tract infections.1 Polypharmacy (being on ≥5 medications) is the strongest predictor of serious 49 
adverse drug events and drug–drug interactions (DDIs).2-4 Some antimicrobials have known 50 
contraindications as a result of drug interactions and should not be prescribed when these 51 
interactions are present. The increasing medication burden in patients with chronic disease has 52 
increased the risk of such co-prescribing. Thus recognition of these clinically relevant DDIs is 53 
crucial. 54 
The extent to which antimicrobial related contraindicated DDI is prevalent is unknown. In 55 
addition, there is paucity of information regarding the most likely medication combinations with 56 
antibacterial or antifungal agents that result in contraindications. The objective of this study was 57 
to examine national-level patterns of contraindications between oral antibacterial or antifungal 58 
agents and patients’ other oral medications in the U.S ambulatory care setting. 59 
 60 
Methods 61 
This cross-sectional study included multiple year pooled data (2003-2011) from the National 62 
Ambulatory Medical Care Survey (NAMCS) and the National Hospital Ambulatory Medical 63 
Care Survey (NHAMCS Outpatient Department).5 Nationally representative ambulatory medical 64 
care service utilization data from visits to non-federally employed, office-based physicians and 65 
outpatient departments of non-institutional, general and short-stay hospital in the U.S are 66 
collected in the NAMCS and NHAMCS.6 These surveys are collected yearly using a multistage 67 
probability sampling design by the National Center for Health Statistics (NCHS) of the Centers 68 
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for Disease Control and Prevention (CDC). An initial list of contraindicated combinations of any 69 
oral antibacterial or antifungal agents with any oral medication was created after extensive 70 
screening of drug information software (Lexi-Comp Online and Micromedex databases).7,8 71 
Subsequently, a second screening of Food and Drug Administration (FDA) approved labeling of 72 
each contraindicated medication, whether it was the precipitant drug or the interacting drug, was 73 
performed to confirm the final list of contraindicated combinations (Table 1). The words 74 
“contraindicated”, “avoid”, or “should not be used” were utilized to identify presence of 75 
contraindication within the FDA approved labeling. 76 
Visits by adults in NAMCS and NHAMCS who were prescribed an antibacterial or antifungal 77 
agent during an ambulatory care visit were identified. The presence of a contraindicated DDI 78 
between oral antibacterial/antifungal agents prescribed and patients’ other oral medications was 79 
calculated looking both at all DDIs (the denominator was the prescription of any 80 
antibacterial/antifungal agent while the numerator was the co-prescription of any contraindicated 81 
interacting medication) and at specific DDIs (the denominator was the prescription of specific 82 
antibacterial/antifungal agents while the numerator was the co-prescription of specific 83 
contraindicated interacting medications). National estimates were obtained by adjusting for the 84 
complex survey design of NAMCS/NHAMCS. Findings with Relative Standard Error (RSE) > 85 
30% (unweighted sample size < 30) were not reported as these were deemed unreliable 86 
estimates. Sampling variability of an estimate that may arise by chance due to only few sample 87 
surveyed during data collection rather than the entire population is primarily measured by 88 
standard error. Percentage of RSE is calculated by the standard error as a percentage of the 89 
estimate. NCHS considers >30% RSE as unreliable. Unweighted sample size refers to the sample 90 
where the complex survey design of NAMCS/NHAMCS have not been adjusted to obtain the 91 
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U.S nationally representative sample.  Medication use was ascertained by using Multum Lexicon 92 
Code as well as Generic Drug Code in the database. SAS version 9.4 (SAS institute Inc., Cary, 93 
NC, USA) was used to conduct all analyses. 94 
 95 
Results 96 
Looking at all contraindicated DDIs from 2003 to 2011, 1,235,000 ambulatory care visits 97 
(proportion = 0.52%, 95% CI 0.29 to 0.74%) involved prescribing of oral antibacterial or 98 
antifungal agent, which was contraindicated due to a drug interaction. The denominator in this 99 
case was the prescription of any antibacterial/antifungal agent. Looking at specific 100 
contraindicated DDIs, macrolide-containing products (erythromycin or clarithromycin) and 101 
fluoroquinolones were the most prevalent antimicrobials involved in these contraindicated 102 
combinations. The denominator in the former case was the prescription of erythromycin or 103 
clarithromycin, while the denominator in the later case was the prescription of a fluoroquinolone. 104 
The most common contraindication was simultaneous use of macrolide-containing products with 105 
statin medication (simvastatin or lovastatin) (841,864 visits, proportion = 1.91%, 95% CI 0.96 to 106 
2.86%). The next most common combination was fluoroquinolones with antiarrhythmic agents 107 
(amiodarone, sotalol, quinidine, or procainamide) (365,622 visits, proportion = 0.19%, 95% CI 108 
0.06 to 0.32%). Other medications did not reach reliable estimates. 109 
 110 
Discussion 111 
In U.S ambulatory care setting, an oral antibacterial or antifungal agent resulting in a 112 
contraindicated DDI was prescribed in more than a million visits during an 8-year time period. 113 
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Providers should be especially cognizant of the potential for DDIs when prescribing macrolides 114 
and fluoroquinolones, which were the source of the majority of these DDIs. 115 
The use of certain macrolides in combination with statins can lead to life-threatening 116 
rhabdomyolysis and subsequent acute kidney injury. Statins are major cytochrome P450 3A4 117 
(CYP3A4) substrates, which are strongly inhibited by macrolides such as clarithromycin and 118 
erythromycin. This results in an increase in the systemic exposure to statins. For instance, the 119 
area under the curve (AUC) of simvastatin increases by approximately 100% and 300%, 120 
respectively.10,11 A similar increase in AUC is expected with lovastatin because of similar 121 
pharmacokinetics and metabolism by via the CYP3A4 pathway.12,13 122 
The use of fluoroquinolones is contraindicated with some anti-arrhythmic agents because both 123 
can cause QTc prolongation, potentially resulting in a life-threatening arrhythmia - torsades de 124 
pointes.14 Although this interaction is listed as a contraindication according to FDA approved 125 
labeling, some clinicians may consider using these agents simultaneously based on patient 126 
specific circumstances such as baseline risk, comorbidities, and the availability of alternative 127 
therapies. Nonetheless, prescribers should be cautious about this interaction, assess the risk of 128 
arrhythmia, and consider alternative antimicrobial agents, if possible, for patients on anti-129 
arrhythmic agents. If avoidance is not possible, ECG monitoring should be performed and the 130 
shortest possible antimicrobial therapy course should be considered.  It would have been 131 
interesting to evaluate the duration of the therapy with antimicrobial therapy in these situations.  132 
However, NAMCS and NHAMCS are annual cross-sectional surveys and do not collect 133 
information related to the duration of prescriptions. 134 
The primary limitation of this study is that we did not have information regarding the clinical 135 
impact of these contraindicated drug interactions because we were limited to information 136 
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available in the datasets. It is possible that only a small subset of patients exposed to these 137 
interactions had an adverse event. Nonetheless, the incidence of the DDIs themselves is 138 
meaningful. Also, in some circumstances the contraindications may not be absolute depending 139 
on patient specific circumstances. This cannot be gauged from the data alone, and clinical 140 
judgment may warrant prescribing a contraindicated combination, when the benefits outweigh 141 
the risks. Finally, we were only able to include databases until the year 2011 because this is the 142 
most recent year released by the CDC. Therefore, it is unknown if there has been a more recent 143 
change in prescribing practices. 144 
The most common contraindicated oral drug-antibacterial agent interactions in U.S ambulatory 145 
visits, were macrolides (erythromycin/clarithromycin) in combination with statins 146 
(simvastatin/lovastatin), followed by fluoroquinolones in combination with antiarrhythmic 147 
agents. Providers should be aware of these potential contraindications when prescribing 148 
antibiotics. 149 
 150 
 151 
 152 
 153 
 154 
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Table 1. List of Contraindicated Antimicrobials and Patients’ Other Medications 
Contraindicated medications  Antimicrobials Clinical relevance 
Atorvastatin Posaconazole Rhabdomyolysis 
Simvastatin, lovastatin Erythromycin, clarithromycin, itraconazole, posaconazole Rhabdomyolysis 
Alfuzosin Itraconazole, posaconazole Torsades de Pointes 
Amiodarone, procainamide, quinidine, 
sotalol 
Levofloxacin, gemifloxacin, moxifloxacin, ciprofloxacin, 
ofloxacin, norfloxacin, sparfloxacin, gatifloxacin, 
erythromycin, clarithromycin Torsades de Pointes 
Cisapride 
Erythromycin, clarithromycin, fluconazole, itraconazole, 
voriconazole Torsades de Pointes 
Dofetilide 
Erythromycin, clarithromycin, itraconazole, 
trimethoprim/sulfamethoxazole Torsades de Pointes 
Dronedarone Clarithromycin, itraconazole, voriconazole Torsades de Pointes 
Erythromycin Fluconazole Torsades de Pointes 
Quinidine Fluconazole, itraconazole, posaconazole, voriconazole 
Torsades de Pointes and 
hypotension 
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Quinine Erythormycin Torsades de Pointes 
Ivabradine, ranolazine Clarithromycin, itraconazole Torsades de Pointes 
Pimozidea 
Erythromycin, clarithromycin, fluconazole, itraconazole, 
posaconazole, voriconazole Torsades de Pointes 
Terfenadine, astemizole Erythromycin, clarithromycin, fluconazole, voriconazole Torsades de Pointes 
Eletriptan Clarithromycin, itraconazole 
Mycocardial infarction 
and stroke 
Ticagrelor Clarithromycin, itraconazole, voriconazole Dyspnea and bleeding 
Methadone Itraconazole 
Respiratory depression 
and hypotension 
Felodipine Clarithromycin, itraconazole, voriconazole Hypotension 
Tizanidine Ciprofloxacin 
Hypotension and 
neurologic toxicity 
Disulfiram Metronidazole, tinidazole 
Neuropsychiatric 
toxicity 
Ergotamine 
Erythromycin, clarithromycin, itraconazole, posaconazole, 
voriconazole Ergotism 
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Phenelzine, isocarboxazida Linezolid Serotonin syndrome 
Eplerenone Clarithromycin, itraconazole 
Hyperkalemia and 
nephrotoxicity 
Everolimus Itraconazole, voriconazole 
Bone marrow 
suppression and 
hypokalemia 
Sirolimus 
Erythromycin, clarithromycin, itraconazole, posaconazole, 
voriconazole 
Bone marrow 
suppression and 
hypokalemia 
Erythromycin Clindamycin Antagonism 
Carbamazepime, phenobarbital, rifampin, 
rifabutina  Voriconazole 
Reduced efficacy of 
voriconazole 
Dronedarone, everolimus, ivabradinea, 
praziquantel, omeprazole, esomeprazole, 
ticagrelor, apixabana, rivaroxaban, 
edoxabana, dabigatran, ranolazine, quinine Rifampin 
Reduced efficacy of 
contraindicated 
medications 
aThese drugs were not available in the  National Ambulatory Medical Care Survey (NAMCS) and the National Hospital Ambulatory Medical Care 
Survey (NHAMCS Outpatient Department) 
 
